EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR) mutations have been recently discovered and EGFR- -tyrosine kinase inhibitor (TKI treatment has been played an important role in treating advanced NSCLC, especially for EGFR mutation patients [8-10].